Literature DB >> 12579211

The expression of c-erbB-1 and c-erbB-2 in Iranian patients with gastric carcinoma.

Abbas Ghaderi1, Mohammad Vasei, S A Maleck-Hosseini, Behronz Gharesi-Fard, Maliheh Khodami, Mehrnoosh Doroudchi, Helmout Modjtahedi.   

Abstract

To assess the significance of epidermal growth factor receptor family members, the overexpression of c-erbB-1 and c-erbB-2 was retrospectively investigated in 146 southern Iranian gastric cancer patients. Indirect immunostaining was used to evaluate the expression of these two receptors in formalin-fixed paraffin-embedded tissue samples. c-ErbB-1 expression was observed in 47 (32.2%) and c-erbB-2 expression was observed in 24 (16.4%) of tumors. Significant positive correlations were observed between c-erbB-1 expression and tumor size, local invasion, lymph node involvement and tumor stage. There was also a negative correlation between c-erbB-2 expression and tumor stage. These results may suggest the contribution of c-erbB-1 molecule in progression of gastric carcinomas in southern Iranian patients. Moreover, the relatively high percentage of c-erbB-2 positive tumors may provide a useful target for the immunotherapy of these cancers.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12579211     DOI: 10.1007/BF03036740

Source DB:  PubMed          Journal:  Pathol Oncol Res        ISSN: 1219-4956            Impact factor:   3.201


  31 in total

1.  Expression of epidermal growth factor receptor and CD44 splicing variants sharing exons 6 and 9 on gastric and esophageal carcinomas: a two-color flow-cytometric analysis.

Authors:  S Koyama; T Maruyama; S Adachi
Journal:  J Cancer Res Clin Oncol       Date:  1999       Impact factor: 4.553

2.  Antiangiogenic and antitumor activity of anti-epidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human GEO colon cancer cells.

Authors:  F Ciardiello; R Bianco; V Damiano; G Fontanini; R Caputo; G Pomatico; S De Placido; A R Bianco; J Mendelsohn; G Tortora
Journal:  Clin Cancer Res       Date:  2000-09       Impact factor: 12.531

3.  Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer.

Authors:  Charles L Vogel; Melody A Cobleigh; Debu Tripathy; John C Gutheil; Lyndsay N Harris; Louis Fehrenbacher; Dennis J Slamon; Maureen Murphy; William F Novotny; Michael Burchmore; Steven Shak; Stanford J Stewart; Michael Press
Journal:  J Clin Oncol       Date:  2002-02-01       Impact factor: 44.544

4.  Evaluation of the epidermal growth factor receptor (EGFR) and c-erbB-2 in superspreading-type and penetrating-type gastric carcinoma.

Authors:  K Aoyagi; K Kohfuji; S Yano; N Murakami; M Miyagi; J Takeda; K Shirouzu
Journal:  Kurume Med J       Date:  2001

Review 5.  Growth factors in progression of human esophageal and gastric carcinomas.

Authors:  K Yoshida; W Yasui; H Ito; E Tahara
Journal:  Exp Pathol       Date:  1990

Review 6.  The HER-2/neu oncogene in tumors of the gastrointestinal tract.

Authors:  J S Ross; B J McKenna
Journal:  Cancer Invest       Date:  2001       Impact factor: 2.176

Review 7.  Trastuzumab in the treatment of non-small cell lung cancer.

Authors:  Christopher G Azzoli; Lee M Krug; Vincent A Miller; Mark G Kris; Robert Mass
Journal:  Semin Oncol       Date:  2002-02       Impact factor: 4.929

8.  The expression of p53, c-erbB-1 and c-erbB-2 molecules and their correlation with prognostic markers in patients with head and neck tumors.

Authors:  Bijan Khademi; Farzaneh Mohammadalizadeh Shirazi; Mohammad Vasei; Mehrnoosh Doroudchi; Behrouz Gandomi; Helmout Modjtahedi; Abdul Mohammad Pezeshki; Abbas Ghaderi
Journal:  Cancer Lett       Date:  2002-10-28       Impact factor: 8.679

9.  Antitumor activity of combinations of antibodies directed against different epitopes on the extracellular domain of the human EGF receptor.

Authors:  H Modjtahedi; S A Eccles; G Box; J Styles; C J Dean
Journal:  Cell Biophys       Date:  1993 Jan-Jun

Review 10.  Neu and its ligands: from an oncogene to neural factors.

Authors:  E Peles; Y Yarden
Journal:  Bioessays       Date:  1993-12       Impact factor: 4.345

View more
  6 in total

1.  An independent survival prognostic role for human epidermal growth factor receptor 2 in gastric cancer: evidence from a meta-analysis.

Authors:  Y Wang; L He; Y Cheng
Journal:  Clin Transl Oncol       Date:  2017-07-05       Impact factor: 3.405

2.  Expression of nucleostemin, epidermal growth factor and epidermal growth factor receptor in human esophageal squamous cell carcinoma tissues.

Authors:  Gongyuan Zhang; Qiao Zhang; Qinxian Zhang; Lei Yin; Shenglei Li; Kuisheng Cheng; Yunhan Zhang; Honghui Xu; Weidong Wu
Journal:  J Cancer Res Clin Oncol       Date:  2009-10-13       Impact factor: 4.553

3.  Overexpression of Grb2/HER2 signaling in Chinese gastric cancer: their relationship with clinicopathological parameters and prognostic significance.

Authors:  Guan Zhen Yu; Ying Chen; Jie Jun Wang
Journal:  J Cancer Res Clin Oncol       Date:  2009-04-01       Impact factor: 4.553

4.  HER2 as a Prognostic Marker in Gastric Cancer - A Systematic Analysis of Data from the Literature.

Authors:  Jan Trøst Jørgensen; Maria Hersom
Journal:  J Cancer       Date:  2012-03-12       Impact factor: 4.207

5.  Targeting EGFR and HER-2 with cetuximab- and trastuzumab-mediated immunotherapy in oesophageal squamous cell carcinoma.

Authors:  Y Kawaguchi; K Kono; K Mimura; F Mitsui; H Sugai; H Akaike; H Fujii
Journal:  Br J Cancer       Date:  2007-07-10       Impact factor: 7.640

6.  The Prognostic Significance of Her2-Neu Over expression in Gastric Carcinomas.

Authors:  J Ansari; A Chehrei; M Amini; S H Alizade; M H Sanei
Journal:  Iran J Cancer Prev       Date:  2011
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.